ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 35 Issue 4
Apr.  2019
Turn off MathJax
Article Contents

Advances in the understanding and treatment of liver fibrosis in traditional Chinese medicine

DOI: 10.3969/j.issn.1001-5256.2019.04.006
Research funding:


  • Received Date: 2019-01-20
  • Published Date: 2019-04-20
  • Liver fibrosis is commonly seen in various chronic liver diseases. In history, traditional Chinese medicine ( TCM) clinical practice based on syndrome differentiation and treatment formed unique experience in the diagnosis and treatment of liver fibrosis; in recent years, studies based on experimental exploration and evidence-based medicine have formed effective Chinese patent drugs and experienced prescriptions for the treatment of liver fibrosis, as well as integrated traditional Chinese and Western medicine regimens. With the improvement in the quality of TCM drugs and the development of related clinical studies, new TCM drugs with stable quality and marked clinical effect will be launched for the treatment of liver fibrosis, so as to meet the clinical needs of patients with chronic liver diseases and promote the modern and international development of TCM.


  • loading
  • [1]WALLACE MC, FRIEDMAN SL, MANN DA. Emerging and disease-specific mechanisms of hepatic stellate cell activation[J]. Semin Liver Dis, 2015, 35 (2) :107-118.
    [2]WANLESS IR, NAKASHIMA E, SHERMAN M. Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis[J]. Arch Pathol Lab Med, 2000, 124 (11) :1599-1607.
    [3]LOK AS. Hepatitis:Long-term therapy of chronic hepatitis B reverses cirrhosis[J]. Nat Rev Gastroenterol Hepatol, 2013, 10 (4) :199-200.
    [4]LIU CH, LIU P, HU YY, et al. Advances in clinical and basic research on anti-hepatic fibrosis of traditional Chinese medicine[J]. World Sci Technol Modern Tradit chin Med, 2007, 9 (2) :112-119. (in Chinese) 刘成海, 刘平, 胡义扬, 等.中医药抗肝纤维化临床与基础研究进展[J].世界科学技术-中医药现代化, 2007, 9 (2) :112-119.
    [5]YANG SX, SUN SL, ZHANG XW. Qianshi collection (episode4, experience and salary transfer of famous Chinese medicine doctors) [M]. Xi'an:Shaanxi Science and Technology Press, 2003:84-87. (in Chinese) 杨世兴, 孙塑伦, 张学文.碥石集 (第4集, 著名中医学家经验传薪) [M].西安:陕西科学技术出版社, 2003:84-87.
    [6]BEI RP. Jiang Chunhua's experience in the treatment of liver cirrhosis[J]. J Tradit Chin Med, 1983, 2:12-14. (in Chinese) 贝润浦.姜春华治疗肝硬化的经验[J].中医杂志, 1983, 2:12-14.
    [7]LIU C, HU Y, XU L, et al. Effect of Fuzheng Huayu formula and its actions against liver fibrosis[J]. Chin Med, 2009, 4:12.
    [8]ZHOU T, LIU CH, CHEN Y, et al. Guiding role of qi-blood theory in treatment of liver fibrosis due to chronic liver diseases[J]. Acta Univ Tradit Med Sin Pharmacol Shanghai, 2007, 21 (2) :34-36. (in Chinese) 周滔, 刘成海, 陈园, 等.气血理论在慢性肝病肝纤维化治疗中的指导作用[J].上海中医药大学学报, 2007, 21 (2) :34-36.
    [9]Chinese Association of lntegrative Medicine, Liver Disease Committee. Guideline for the diagnosis and treatment of liver fibrosis with integrative medicine[J]. Chin J Integr Tradit West Med Liver Dis, 2006, 16 (5) :316-320. (in Chinese) 中国中西医结合学会肝病专业委员会.肝纤维化中西医结合诊疗指南[J].中西医结合肝病杂志, 2006, 16 (5) :316-320.
    [10]LIU P, HU YY, LIU C, et al. Multicenter clinical study on Fuzhenghuayu capsule against liver fibrosis due to chronic hepatitis B[J]. World J Gastroenterol, 2005, 11 (19) :2892-2899.
    [11]HASSANEIN T, BOX TD, TONG MJ, et al. A phase II, randomized, placebo-controlled, double-blind, multicenter study to assess the antifibrotic activity of Fuzheng Huayu in chronic hepatitis C patients with hepatic fibrosis[J]. Hepatol Int, 2014, 8:s308-s309.
    [12]ZHOU GD, LI WS, ZHAO JM, et al. Clinical pathological study on the mechanism of effect of Fufangbiejiaruanganpian in treatment of liver fibrosis[J]. Med J Chin PLA, 2004, 29 (7) :563-564. (in Chinese) 周光德, 李文淑, 赵景民, 等.复方鳖甲软肝片抗肝纤维化机制的临床病理研究[J].解放军医学杂志, 2004, 29 (7) :563-564.
    [13]YIN SS, WANG BE, WANG TL, et al. The effect of Cpd 861on chronic hepatitis B related fibrosis and early cirrhosis:a randomized, double blind, placebo controlled clinical trial[J].Chin J Hepatol, 2004, 12 (8) :467-470. (in Chinese) 尹珊珊, 王宝恩, 王泰龄, 等.复方861治疗慢性乙型肝炎肝纤维化与早期肝硬化的临床研究[J].中华肝脏病杂志, 2004, 12 (8) :467-470.
    [14]CAI ST. Clinical study on early liver fibrosis of chronic hepatitis B treated with Auluohuaxianwan[D]. Fuzhou:Fujian University of Traditional Chinese Medicine, 2017. (in Chinese) 蔡少桐.安络化纤丸阻断慢性乙型肝炎早期肝纤维化的临床研究[D].福州:福建中医药大学, 2017.
    [15]TANG LR, GUO T, TAO YY, et al. A systematic review of combinative effects of Fuzheng Huayu capsule with nucleotide analogues on liver fibrosis due to chronic hepatitis B[J]. Chin J Integr Tradit West Med Liver Dis, 2013, 23 (3) :183-187. (in Chinese) 唐礼瑞, 郭涛, 陶艳艳, 等.扶正化瘀胶囊联合核苷 (酸) 类药物治疗慢性乙型肝炎肝纤维化的初步系统评价[J].中西医结合肝病杂志, 2013, 23 (3) :183-187.
    [16]ZHAO CQ, XU LM. Progress of clinical studies on Fuzheng Huyu capsule/tablet in treating liver fibrosis and liver cirrhosis[J]. World Chin Med, 2014, 9 (5) :561-567. (in Chinese) 赵长青, 徐列明.扶正化瘀胶囊/片治疗肝纤维化和肝硬化的临床研究进展[J].世界中医药, 2014, 9 (5) :561-567.
    [17]CHEN Y, YANG YP. The role of traditional Chinese medicine in blocking and reversing hepatic fibrosis:Current status, hope, and challenge[J]. J Clin Hepatol, 2018, 34 (4) :689-693. (in Chinese) 陈艳, 杨永平.中医药阻断逆转肝纤维化的现状、希望与挑战[J].临床肝胆病杂志, 2018, 34 (4) :689-693.
    [18]HUANG ZJ, ZENG CP. The therapy of entecavir combined with Anluo Huaxian capsule on HBe Ag positive chronic hepatitis B-related liver fibrosis in 134 cases[J]. Chin J Integr Tradit West Med Liver Dis, 2016, 26 (2) :74-75. (in Chinese) 黄志杰, 曾翠萍.恩替卡韦联合安络化纤丸治疗HBe Ag阳性慢性乙型肝炎肝纤维化134例[J].中西医结合肝病杂志, 2016, 26 (2) :74-75.
    [19]CHEN HB. Clinical effect of entecavir combined with Dahuang Zhechong pills in the treatment of hepatitis B liver fibrosis[J].Clin Res Pract, 2018, 3 (5) :133-134. (in Chinese) 陈宏斌.恩替卡韦联合大黄蛰虫丸治疗乙型肝炎肝纤维化的临床效果[J].临床医学研究与实践, 2018, 3 (5) :133-134.
    [20]WANG H, ZHAO YL, XU KC, et al. Clinical and pathological study on effects of Qianggan capsule combined lamivudine on hepatic fibrosis in patients with chronic hepatitis B[J]. Chin J Integr Trad West Med, 2006, 26 (11) :978-980. (in Chinese) 王华, 赵延龙, 徐克成, 等.强肝胶囊联合拉米夫定治疗慢性乙型肝炎肝纤维化的临床病理观察[J].中国中西医结合杂志, 2006, 26 (11) :978-980.
    [21]LUO GA, WANG YM, CAO J, et al. Studies on establishment of modern quality standards system of traditional Chinese medicine in China[J]. World Sci Technol Modern Tradit Chin Med, 2002, 4 (4) :5-11, 79. (in Chinese) 罗国安, 王义明, 曹进, 等.建立我国现代中药质量标准体系的研究[J].世界科学技术-中医药现代化, 2002, 4 (4) :5-11, 79.
    [22]LI B, PIAO JH. Study on the quality control of bioactivity in traditional Chinese medicine[J]. Drug Stand China, 2012, 13 (1) :5-8. (in Chinese) 李波, 朴晋华.中药生物活性质量控制的思考[J].中国药品标准, 2012, 13 (1) :5-8.
    [23]LAM W, REN Y, GUAN F, et al. Mechanism based quality control (MBQC) of herbal products:A case study YIV-906 (PHY906) [J]. Front Pharmacol, 2018, 9:1324.
    [24]SUN Y, ZHOU J, WANG L, et al. New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment[J]. Hepatology, 2017, 65 (5) :1438-1450.
    [25]XU S, WANG Y, TAI DCS, et al. qFibrosis:A fully-quantitative innovative method incorporating histological features to facilitate accurate fibrosis scoring in animal model and chronic hepatitis B patients[J]. J Hepatol, 2014, 61 (2) :260-269.
    [26]GUO J, DONG Y, TANG JY. Discussion on clinical problems about bases of new drug oftraditional Chinese medicine development[J]. China J Chin Mater Med, 2017, 42 (5) :844-847. (in Chinese) 郭洁, 董宇, 唐健元.中药复方新药立题依据的临床问题探讨[J].中国中药杂志, 2017, 42 (5) :844-847.
    [27]Writing Group of Principles of Dialectics of Nature. Principles of dialectics of nature[M]. Shanghai:Shanghai Scientific&Technical Publishers, 1985:202-214. (in Chinese) 《自然辩证法原理》编写组.自然辩证法原理[M].上海:上海科技出版社, 1985:202-214.
    [28]ZHAO W, ZHAO ZM, WANG ZT, et al. Compare the effects of traditional Chinese prescriptions formulae for promoting blood circulation on liver fibrosis induced by DMN in rats[J]. Pharmocol Clin Chin Mater Med, 2012, 28 (3) :15-18. (in Chinese) 赵韦, 赵志敏, 王峥涛, 等.活血化瘀类方抗肝纤维化疗效比较[J].中药药理与临床, 2012, 28 (3) :15-18.
    [29]GUO T, LIU ZL, ZHAO Q, et al. A combination of astragaloside I, levistilide A and calycosin exerts anti-liver fibrosis effects in vitro and in vivo[J]. Acta Pharmacol Sin, 2018, 39 (9) :1483-1492.
  • 加载中


    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (2147) PDF downloads(580) Cited by()
    Proportional views


    DownLoad:  Full-Size Img  PowerPoint